[Biologic effects and possible therapeutic use of the granulocyte-macrophage colony-stimulating factor. Modern treatment of leukopenia].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Transliterated Title:
      Bioloska dejstva i moguća terapijska uptreba stimulantnog faktora granulocito-makrofagnih kolonija. Savreno lecenje leukopenija.
    • Source:
      Publisher: Srpski Lekarski Drustvo Country of Publication: Serbia NLM ID: 0027440 Publication Model: Print Cited Medium: Print ISSN: 0370-8179 (Print) Linking ISSN: 03708179 NLM ISO Abbreviation: Srp Arh Celok Lek Subsets: MEDLINE
    • Publication Information:
      Publication: Beograd : Srpski Lekarski Drustvo
      Original Publication: Belgrade.
    • Subject Terms:
    • Abstract:
      This review is a brief overview of recent advances in biology as well as in potential clinical application of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Biologically active rhGM-CSF is a recombinant human protein expressed in Escherichia coli. GM-CSF is produced by nontransformed (T-lymphocytes, trophoblasts, keratinocytes, osteoblasts, tracheal epithelial cells, renal mesangial cells, endothelial cells, macrophages, fibroblasts, smooth muscle cells) and transformed (murine plasmocytoma, bladder carcinoma HIBY cell line, anaplastic carcinoma of the gall bladder, Yoshida sarcoma cell line, HC3T3-osteoblast cell line) cells. RhGM-CSF increases the number of circulating neutrophils, monocytes and eosinophils and increases chemotactic, microcidal killing and cytotoxic activity of monocytes and granulocytes. The present clinically relevant uses of rhGM-CSF two general areas: restoration of haematopoietic dysfunction by raising cell counts from suppressed to normal levels, and augmentation of host defence against infection. Thus, rhGM-CSF reduces risk of infections. In addition, rhGM-CSF may increase tumour cell destruction in some malignant diseases. RhGM-CSF produces dose-dependent toxicity consisting of myalgic fever, fluid retention and serosal effusions.
    • Number of References:
      9
    • Accession Number:
      0 (Recombinant Proteins)
      83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
    • Publication Date:
      Date Created: 19930801 Date Completed: 19950525 Latest Revision: 20091111
    • Publication Date:
      20231215
    • Accession Number:
      7725160